What is the prior authorization process for orforglipron (Foundayo)?

Most commercial insurance plans require prior authorization (PA) for orforglipron (branded Foundayo) because it launched in April 2026. The typical PA criteria mirror Wegovy and Zepbound: BMI of 30 or above, or BMI of 27 or above with a qualifying comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnea. Your prescribing clinician submits the PA; approval usually takes two to six weeks for standard review. If approved, Eli Lilly's Foundayo savings card reduces the copay to as low as $25 per month for commercially insured patients.

Is orforglipron (Foundayo) covered by insurance?

Coverage is expanding as plans update their 2026 formularies. For commercially insured patients who receive prior authorization, the Foundayo savings card brings the cost to as low as $25 per month. Medicare and Medicaid patients are not eligible for manufacturer savings cards; those plans have separate coverage pathways. Self-pay via LillyDirect starts at $149 per month at the lowest starting dose.

When was orforglipron FDA approved?

Orforglipron was approved by the FDA on April 1, 2026, making it the first FDA-approved oral non-peptide GLP-1 receptor agonist. It is manufactured by Eli Lilly and branded Foundayo. The approval was for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related comorbidity.

Drug profile

Orforglipron (Foundayo): the 2026 buyer's guide

Orforglipron, branded Foundayo, is Eli Lilly's small-molecule GLP-1 receptor agonist, taken as a daily oral tablet rather than a weekly injection. The FDA approved it for chronic weight management on April 1, 2026, making it the first oral non-peptide GLP-1 to reach market. It is available via LillyDirect, US retail pharmacies and telehealth programs. Below: what the trials show, what it costs and how it fits against the injectable GLP-1s.

Compare Orforglipron prices →

Key takeaways

Orforglipron is a daily oral tablet, FDA-approved for chronic weight management since 2026.
In the ATTAIN-1 trial, mean weight loss was 12.4% over 72 weeks, with 36% of patients losing 15% or more of body weight.
It carries the GLP-1 class boxed warning for thyroid C-cell tumor risk, and is not for people with a personal or family history of medullary thyroid carcinoma or MEN2.
Cash, insurance and compounded prices differ widely. See the cost breakdown below, and the all-in program costs on the chart.

Active ingredient

orforglipron

Manufacturer

Eli Lilly

FDA-approved for

chronic weight management (2026)

Schedule

Daily · oral tablet (the first FDA-approved oral non-peptide GLP-1)

What Orforglipron costs in 2026

There is no one price. What you pay depends on which path you take:

Retail cash

Available at US retail pharmacies since the April 2026 launch; verify the cash list price with the pharmacy

No insurance, no program. The list price before any discount.

Manufacturer direct

$149/mo self-pay at the lowest dose via LillyDirect (Foundayo savings program)

Cash-pay straight from the maker (NovoCare or LillyDirect).

Insurance + prior authoften lowest

As low as $25/mo for eligible commercially insured patients with the Foundayo savings card; coverage varies by plan

If your plan covers it, usually the lowest. Expect a prior authorization first.

Compounded (503A)

No legal compounded orforglipron market. The molecule is FDA-approved only as branded Foundayo and was never on the FDA shortage list, so 503A compounding of orforglipron is not permitted.

Same molecule from a compounding pharmacy. Cheapest path, most regulatory risk.

Telehealth programs add a membership fee on top of the medication cost (typically $40-$200/mo). For all-in monthly costs by program, see the chart, the full GLP-1 cost guide, or calculate your exact all-in cost by drug, coverage and state.

Orforglipron (Foundayo) prior authorization: step by step

Because Foundayo launched in April 2026, most commercial insurance plans require prior authorization (PA) before they will cover it. Coverage is expanding as plans update their formularies, but PA is the standard path for now. Here is what the process looks like in practice.

Confirm your plan's criteria before submitting.Call member services (number on your insurance card) or check your plan's formulary online. Plans that cover Foundayo typically require: BMI of 30 or above, or BMI of 27 or above with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea). Some plans also require documentation of a supervised diet attempt.
Your prescribing clinician submits the PA request. Telehealth programs (Ro, PlushCare, Found) that prescribe orforglipron handle this on your behalf. If you see your own doctor, ask their office to submit the PA to your pharmacy benefit manager. The request must include your diagnosis code (E66.9 for obesity, or the specific comorbidity ICD-10 if BMI is 27 to 29.9), your current BMI from a recent clinic note, and any supporting documentation the plan requires.
Wait for the determination. Commercial PA decisions typically take two to six weeks for standard review. Expedited review (for urgent clinical situations) must be decided within 72 hours. Ask for expedited if your clinician documents that a delay would harm your health.
If approved: use the Foundayo savings card.Eli Lilly's Foundayo savings card reduces copays to as low as $25 a month for commercially insured patients. Available at LillyDirect and through participating pharmacies. Medicare and Medicaid patients are not eligible for manufacturer savings cards; those plans have separate coverage pathways.
If denied: appeal citing the ATTAIN-1 trial. An initial PA denial is not final. The ATTAIN-1 registration trial (NEJM, 2025) showed 12.4% mean weight loss at 72 weeks versus placebo. A PA appeal letter citing the trial outcomes and the FDA label approval date (April 2026) gives the reviewer the clinical basis to override the denial. See the appeal letter templates for a starting point, and the PA step-by-step guide for the full appeal timeline.

Because orforglipron was newly approved in April 2026, payer formulary decisions are still rolling out. Check back as more plans publish their Foundayo coverage criteria.

Who it's for

Adults with obesity (BMI ≥30), or BMI ≥27 with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity. Mirrors the Wegovy and Zepbound obesity criteria.

What the trials show

Orforglipron's registration trial was ATTAIN-1 (NEJM, 2025). At 72 weeks at the maximum dose, mean weight loss was 12.4% (10.5 percentage points greater than placebo). 80% of patients lost at least 5% of body weight; 36% lost at least 15%. Real-world results vary; trial patients are typically more adherent and more closely managed than typical telehealth patients.

Dose schedule

Dose levels: 0.8mg, 2.5mg, 5.5mg, 9mg, 14.5mg, 17.2mg. Standard practice is to titrate up monthly, holding at any tolerated dose. Maximum dose is 17.2mg daily; many patients reach goal weight at sub-maximum doses and stay there.

Common side effects

The most commonly reported side effects in the registration trial:

nausea (25-30% in trials)
diarrhea (18-22%)
vomiting (10-14%)
constipation (10%)
abdominal discomfort (8%)

Boxed warning: Risk of thyroid C-cell tumors. Per Foundayo's FDA label (Initial U.S. Approval 2026), the drug carries the GLP-1 class boxed warning based on rodent data and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

How Orforglipron differs from related drugs

First FDA-approved oral non-peptide GLP-1. Cheaper to manufacture and ship than injectable peptides, which lowers the all-in cost of GLP-1 therapy (self-pay from $149/mo). It can be taken any time of day without the food and water restrictions that oral semaglutide (Rybelsus) requires.

Programs that prescribe Orforglipron

These programs in our chart prescribe Orforglipron (with insurance coverage where applicable, or as a cash-pay option). Ranked by overall score.

Some visit links earn us a commission.

Learn more about Orforglipron

References

Trial figures are mean results at the maximum dose in the cited registration trial. Real-world outcomes vary with adherence and clinical management.

Editorial disclosure

GLP Chart is an editorial comparison site. We do not dispense, prescribe or fulfill medications. Talk to a licensed clinician about whether Orforglipron is appropriate for you. Pricing reflects publicly verified rates as of June 22; verify with the manufacturer or your prescriber before committing.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.